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Yan-Ru Lou1,2, Tai Chong Toh3,4, Yee Han Tee5,6 & Hanry Yu1,5,6,7,8,9,10
25-Hydroxyvitamin D3 [25(OH)D3] has recently been found to be an active hormone. Its biological 
actions are demonstrated in various cell types. 25(OH)D3 deficiency results in failure in bone formation 
and skeletal deformation. Here, we investigated the effect of 25(OH)D3 on osteogenic differentiation 
of human mesenchymal stem cells (hMSCs). We also studied the effect of 1α,25-dihydroxyvitamin 
D3 [1α,25-(OH)2D3], a metabolite of 25(OH)D3. One of the vitamin D responsive genes, 25(OH)D3-24-
hydroxylase (cytochrome P450 family 24 subfamily A member 1) mRNA expression is up-regulated 
by 25(OH)D3 at 250–500 nM and by 1α,25-(OH)2D3 at 1–10 nM. 25(OH)D3 and 1α,25-(OH)2D3 at a 
time-dependent manner alter cell morphology towards osteoblast-associated characteristics. The 
osteogenic markers, alkaline phosphatase, secreted phosphoprotein 1 (osteopontin), and bone 
gamma-carboxyglutamate protein (osteocalcin) are increased by 25(OH)D3 and 1α,25-(OH)2D3 in a 
dose-dependent manner. Finally, mineralisation is significantly increased by 25(OH)D3 but not by 
1α,25-(OH)2D3. Moreover, we found that hMSCs express very low level of 25(OH)D3-1α-hydroxylase 
(cytochrome P450 family 27 subfamily B member 1), and there is no detectable 1α,25-(OH)2D3 product. 
Taken together, our findings provide evidence that 25(OH)D3 at 250–500 nM can induce osteogenic 
differentiation and that 25(OH)D3 has great potential for cell-based bone tissue engineering.
1α ,25-dihydroxyvitamin D3 [calcitriol, 1α ,25-(OH)2D3] is generated through two sequential hydroxylation steps 
of vitamin D3 in the body. The first step is 25-hydroxylation producing 25-hydroxyvitamin D3 [calcidiol, 25(OH)
D3] in the liver, and the second step is 1α -hydroxylation mediated by 25(OH)D3-1α -hydroxylase, also called 
cytochrome P450 family 27 subfamily B member 1, (CYP27B1, encoded by the gene CYP27B1) in the kidney1. 
1α ,25-(OH)2D3 exerts its actions via a nuclear vitamin D receptor (VDR) and is regarded as the most active 
form of vitamin D. Since the discovery of CYP27B1 in extra-renal tissues, the intracellular production of 1α ,25-
(OH)2D3 from 25(OH)D3 has been suggested to play an autocrine or a paracrine role in the local regulation of cell 
proliferation and differentiation2,3.
25(OH)D3 is the most abundant vitamin D metabolite in the blood. Its deficiency causes rickets in children 
and osteomalacia in adults4. Osteoporosis and fracture are also closely related to the suboptimal status of 25(OH)
D35–8. Recent studies have demonstrated that 25(OH)D3 at physiological concentrations is as potent as 1α ,25-
(OH)2D3 at pharmacological concentrations in terms of regulating the behaviour of various types of cells both in 
vitro and in vivo9–20.
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Human bone marrow-derived mesenchymal stem cells (hMSCs) can differentiate towards several cell line-
ages including osteoblasts, adipocytes, chondrocytes, and muscle cells21. They are a good cell source for tissue 
engineering and a good model for the study of hormonal effects. The osteogenic differentiation of hMSCs has 
been extensively studied since it could be a potential cell source for the treatment of bone defects, bone loss, 
and osteoporosis. 1α ,25-(OH)2D3 has been shown to induce the osteogenic differentiation of hMSCs22,23, but 
there is not much information about the effects of 25(OH)D3 on these processes. In the present study, we eval-
uated the actions of 25(OH)D3 during osteogenesis of hMSCs in many aspects including cellular morphology, 
osteoblast-related gene expression, protein secretion, and mineralisation. These findings can be further exploited 
for bone tissue engineering applications.
Results
The concentrations of 25(OH)D3 and 1α ,25-(OH)2D3 used in the present study were chosen according to their 
optimal physiological concentrations. The optimal serum concentration of 25(OH)D3 is still under discus-
sion. A serum level of 25(OH)D3 between 75–150 nM can be considered vitamin D sufficiency4. The Institute 
of Medicine recommends the optimal concentration of 25(OH)D3 being 50 nM, International Osteoporosis 
Foundation recommends 75 nM or above, MedlinePlus recommends 75–185 nM, and the Endocrine Society 
recommends 100 nM. We have used 100–500 nM that are no more than ~3 folds higher than the recommended 
optimal serum concentrations. On the other hand, the serum level of 1α ,25-(OH)2D3 is strictly controlled 
between 0.03–0.14 nM24. We have used 0.05–10 nM that are no more than ~70 folds higher than the physiological 
concentrations.
Effect of 25(OH)D3 and 1α,25-(OH)2D3 on 24-hydroxylase in hMSCs. To investigate the osteogenic 
differentiation effects of vitamin D metabolites on hMSCs, we first ensured that hMSCs were responsive to vita-
min D treatments. 24-Hydroxylase, cytochrome P450 family 24 subfamily A member 1, encoded by the gene 
CYP24A1, is regulated by the ligand-bound vitamin D receptor. It has been regarded as one of the most vitamin 
D-responsive genes. Earlier microarray studies showed that CYP24A1 was the most upregulated gene by 25(OH)
D3 and 1α ,25-(OH)2D3 among 38500 human genes20 and by 1α ,25-(OH)2D3 among 3800 human genes25. We 
therefore used its mRNA expression as an indicator of the responsiveness of hMSCs to vitamin D.
500 nM 25(OH)D3 significantly increased the level of CYP24A1 mRNA 1217591 ± 389680 folds (P < 0.001), 
1234651 ± 666181 folds (P < 0.001), and 1503721 ± 364941 folds (P < 0.001) at day 7, 14, and 21, respec-
tively (Fig. 1a). 10 nM 1α ,25-(OH)2D3 significantly increased the level of CYP24A1 mRNA 6113 ± 1851 folds 
(P < 0.001), 6321 ± 2042 folds (P < 0.001), and 4918 ± 1082 folds (P < 0.001) at day 7, 14, and 21, respectively 
(Fig. 1b). Lower concentrations of 25(OH)D3 (250 nM) and 1α ,25-(OH)2D3 (1 nM) also increased the gene 
expression of CYP24A1, but the increase was not statistically significant. This result demonstrates the tran-
scriptional activity of 25(OH)D3 and 1α ,25-(OH)2D3 in hMSCs and suggests that hMSCs respond to vitamin D 
treatments.
CYP27B1 gene expression and 1α-hydroxylation in hMSCs. 25(OH)D3 is metabolised into 1α ,25-
(OH)2D3 by 1α -hydroxylase, cytochrome P450 family 27 subfamily B member 1, encoded by CYP27B1. To clar-
ify whether this occurs in hMSCs, we first measured the mRNA expression of CYP27B1. MCF-7 cell line was 
selected as a positive control as it is well-established in the literature26,27. The hMSCs expressed extremely low 
level of CYP27B1 mRNA, approximately 9.5% of the level expressed in MCF-7 cells (Fig. 2). In addition, 1α ,25-
(OH)2D3 was not detectable by HPLC in the conditioned media of hMSCs treated with 500 nM 25(OH)D3 (data 
not shown). We noticed that the cycle threshold (Ct) values of CYP24A1 were higher than those of CYP27B1 and 
a housekeeping gene ribosomal protein lateral stalk subunit P0 (RPLP0) in hMSCs untreated with vitamin D 
metabolites (Supplementary Fig. 1).
Morphological change of hMSCs during the treatment with 25(OH)D3 and 1α,25-(OH)2D3. To 
test the hypothesis that 25(OH)D3 might play a role in osteogenic differentiation of hMSCs, we first monitored the 
morphological changes of the hMSCs upon the treatment with 25(OH)D3. The hMSCs cultured at a lower density 
in normal growth medium appeared to be big, flat, and spindle-shaped (Fig. 3a); and at a higher density after 
21-day culture they looked more fibroblast-like (Fig. 3b). In the presence of 500 nM 25(OH)D3, some cells started 
to change their morphology as early as day 6 and appeared more polygonal, an osteoblast-associated character-
istic. After 16 days in culture in the presence of 500 nM 25(OH)D3, the cells comprised a relatively homogeneous 
population of polygonal cells. Figure 3c shows a dramatic change in cell morphology in the culture treated with 
500 nM 25(OH)D3 for 21 days. The morphological change was observed to a lesser extent in the culture treated 
with 250 nM 25(OH)D3 for 21 days (data not shown). In the presence of 100 nM 25(OH)D3 for 21 days, the cells 
seemed to be morphologically similar to the untreated hMSCs (data not shown).
Similarly, some of the hMSCs started to exhibit morphological change after 7-day treatment with 10 nM 
1α ,25-(OH)2D3. At day 21 (Fig. 3d), the cells looked the same as those treated with 500 nM 25(OH)D3. 1 nM 
1α ,25-(OH)2D3 caused similar morphological change starting at day 14. 1α ,25-(OH)2D3 lower than 1 nM did not 
change cell morphology.
25(OH)D3 and 1α,25-(OH)2D3 increase the activity of alkaline phosphatase (ALPL) in hMSCs. 
To characterize the derived cell type, we first measured ALPL activity, which is an early marker expressed during 
osteogenesis. ALPL activity was measured immediately at each time point. Due to possible variations in fluo-
rescence signals between measurements, we can compare readings only between treatments at the same time 
point, but not between different time points. To compare the changes in the ALPL activity between time points, 
we present the results as relative ALPL activity in reference to vehicle control at each time point. Compared 
with the vehicle control, ALPL activity of the hMSCs treated with 500 nM 25(OH)D3 for 7 days was 135 ± 7% 
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(P < 0.001, Fig. 4a). ALPL activity of hMSCs treated with 250 nM and 500 nM 25(OH)D3 for 14 days was 137 ± 8% 
(P < 0.001) and 182 ± 12% (P < 0.001), respectively (Fig. 4a). 100 nM 25(OH)D3 did not change ALPL activity.
We also studied the effect of 1α ,25-(OH)2D3 on ALPL activity. 10 nM 1α ,25-(OH)2D3 increased ALPL activity 
to 176 ± 12% (P < 0.001) at day 7 (Fig. 4b). After 14 days 1 nM and 10 nM 1α ,25-(OH)2D3 increased ALPL activity 
to 144 ± 13% (P < 0.001) and 276 ± 66% (P < 0.001), respectively (Fig. 4b). 0.05 nM and 0.1 nM 1α ,25-(OH)2D3 
did not change ALPL activity.
Figure 1. Induction of cytochrome P450 family 24 subfamily A member 1 (CYP24A1) by 25(OH)D3 and 
1α,25-(OH)2D3 in hMSCs. Real-time quantitative PCR was used to determine the induction of CYP24A1 
mRNA in response to 25(OH)D3 (a) and 1α ,25-(OH)2D3 (b) at the indicated concentrations in the hMSCs 
during three weeks of treatment. Relative mRNA expression was normalised to the control gene ribosomal 
protein lateral stalk subunit P0 (RPLP0) and fold inductions were calculated in reference to solvent control 
(0.1% ethanol), which is set as 1. Results are expressed as means ± SD (n = 3, ***P < 0.001).
Figure 2. Cytochrome P450 family 27 subfamily B member 1 (CYP27B1) mRNA expression. Real-time 
quantitative PCR was used to determine the expression of CYP27B1 mRNA in the hMSCs. Relative mRNA 
expression was normalised to the control gene ribosomal protein lateral stalk subunit P0 (RPLP0). Results are 
expressed as means ± SD (n = 3, ***P < 0.001).
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Effects of 25(OH)D3 and 1α,25-(OH)2D3 on the expression of osteoblast-related genes. We 
next examined the effects of 25(OH)D3 on the expression of osteoblast-related genes. Secreted phosphoprotein 1, 
also called osteopontin, encoded by SPP1, was upregulated by 500 nM 25(OH)D3 by 8.9 ± 3.0 folds (P = 0.001), 
8.8 ± 3.8 folds (P = 0.001), and 7.1 ± 4.9 folds (P = 0.012) at day 7, 14, and 21, respectively (Fig. 5a). More impor-
tantly, the only osteoblast-specific gene, bone gamma-carboxyglutamate protein, also called osteocalcin, encoded 
by BGLAP, was significantly increased by 51.1 ± 39.1 folds (P = 0.023) and 48.4 ± 20.4 folds (P = 0.033) by 
500 nM 25(OH)D3 at day 7 and 14, respectively (Fig. 5c). Runt related transcription factor 2, encoded by RUNX2, 
is an osteoblast-related transcription factor28–30. RUNX2 is expressed in both untreated and hormone-treated 
hMSCs and its expression was unaltered by 25(OH)D3 (Fig. 5e). To determine whether 25(OH)D3 affects 
post-transcription of RUNX2, we analysed the protein expression in hormone-treated hMSCs by Western blotting 
and found no change compared with untreated hMSCs (data not shown).
1α ,25-(OH)2D3 showed similar gene regulation pattern despite the different effective concentrations. 10 nM 
1α ,25-(OH)2D3 caused 5.3 ± 1.0-fold (P < 0.001), 5.0 ± 1.7-fold (P < 0.001), and 6.3 ± 1.4-fold (P < 0.001) 
increase in SPP1 mRNA expression at days 7, 14, and 21, respectively (Fig. 5b). BGLAP was increased 10.5 ± 4.1 
folds (P = 0.015) and 10.3 ± 3.2 folds (P = 0.017) by 1 nM 1α ,25-(OH)2D3 at days 7 and 21, respectively (Fig. 5d). 
10 nM 1α ,25-(OH)2D3 caused 23.2 ± 8.5-fold (P < 0.001), 20.4 ± 4.8-fold (P < 0.001), and 21.0 ± 5.3-fold 
(P < 0.001) increase in osteocalcin mRNA expression at days 7, 14, and 21, respectively (Fig. 5d). Again, RUNX2 
mRNA expression was unaltered by 1α ,25-(OH)2D3 (Fig. 5f).
Effects of 25(OH)D3 and 1α,25-(OH)2D3 on the expression and secretion of osteocalcin protein 
in hMSCs. Bone gamma-carboxyglutamate protein, a vitamin K-dependent amino acid γ -carboxyglutamic 
acid, is produced exclusively in osteoblasts and its dental counterpart, the odontoblast. Therefore, the level of 
bone gamma-carboxyglutamate protein is considered as an indicator of cell activity in bone formation. It has 
a high affinity to calcium and plays an important role in mineralization31–33. To measure the secretion of bone 
gamma-carboxyglutamate protein, we used ELISA to measure its concentration in the cell culture medium. 
Compared with the solvent controls, 250 nM 25(OH)D3 at 250–500 nM and 1α ,25-(OH)2D3 at 1–10 nM modestly 
increased bone gamma-carboxyglutamate protein secretion, but the increase is not statistically significant due to a 
low power (Fig. 6a,b). In addition, the intracellular expression of bone gamma-carboxyglutamate protein seemed 
to increase by 25(OH)D3 (Fig. 6d) and modestly by 1α ,25-(OH)2D3 (Fig. 6e).
Effects of 25(OH)D3 and 1α,25-(OH)2D3 on the matrix mineralisation in hMSCs. Mineralisation 
is regarded as a determinant marker for bone formation. Most studies have used von kossa staining to indicate 
Figure 3. Morphological changes of hMSCs during the treatments with 25(OH)D3 or 1α,25-(OH)2D3.  
(a) hMSCs at day 0; (b) 0.1% ethanol-treated hMSCs at day 21; (c) 500 nM 25(OH)D3-treated hMSCs at day 21; 
(d) 10 nM 1α ,25-(OH)2D3-treated hMSCs at day 21. Scale bars: 60 μ m.
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in vitro mineralisation; however, this method has been questioned on its specificity to calcium34. Here, we directly 
measured calcium concentration in the extracellular matrix. In the presence of 500 nM 25(OH)D3, calcium con-
centration (ng/μ g cellular protein) was 47.2 ± 9.9 (P < 0.001) and 14.9 ± 2.0 (P < 0.05) at days 21 and 28, respec-
tively (Fig. 7a). In contrast, 1α ,25-(OH)2D3 at all the concentrations tested did not have any statistically significant 
effect on the calcium deposition in the extracellular matrix at days 21 and 28 (Fig. 7b) due to a low statistic power.
Discussion
For hMSC-based therapy to be successful in in vivo treatment of bone diseases, it is crucial to transplant hMSCs 
with a suitable substance that facilitates their osteogenic differentiation in vivo. Although 1α ,25-(OH)2D3 had 
previously been demonstrated to be efficient in inducing some osteogenic lineage markers in hMSCs, the poten-
tial side effects induced by the usage of 1α ,25-(OH)2D3 at pharmacological concentrations are major drawbacks 
for its in vivo use. This motivated us to evaluate the use of 25(OH)D3 as it has been recognised as an active metab-
olite in various systems.
Our present study demonstrates that 25(OH)D3 is able to induce osteogenesis of hMSCs and offers a potential 
approach to bone tissue engineering and treatment of bone diseases. 25(OH)D3 at 250–500 nM and 1α ,25-(OH)2D3 
at 1–10 nM caused morphological change towards osteoblast-associated characteristics and increased the expression 
of osteogenic markers. Compared with 1α ,25-(OH)2D3, the differentiation-inducing effect of 25(OH)D3 was greater 
given that calcium deposition in the extracellular matrix of 25(OH)D3-treated hMSCs was significantly increased. 
We found that both mRNA and protein expression of RUNX2 was unaltered in the presence of 25(OH)D3 or 1α 
,25-(OH)2D3. Earlier studies showed that RUNX2 expression was not regulated by 1α ,25-(OH)2D3 in human oste-
oblasts35 and upregulated by 25(OH)D3 and 1α ,25-(OH)2D3 in human marrow stromal cells3. The discrepancy may 
reflect a cell type-specific response of RUNX2 to vitamin D. Both RUNX2 and bone gamma-carboxyglutamate pro-
tein exhibit a species-specific response to vitamin D, being inhibited by 1α ,25-(OH)2D3 in mouse28,36,37. In contrast, 
1α ,25-(OH)2D3 directly induces human bone gamma-carboxyglutamate protein via a vitamin D responsive ele-
ment38,39, and its action is not mediated by RUNX2 in human osteoblasts40.
Figure 4. Regulation of ALPL activity by 25(OH)D3 and 1α,25-(OH)2D3 in hMSCs. Alkaline phosphatase 
(ALPL) activity was measured according to the procedure of ELF97 in the hMSCs during two weeks of 
treatments with 25(OH)D3 (a) or 1α ,25-(OH)2D3 (b) at the indicated concentrations. Results are expressed as 
means ± SD (n = 9, ***P < 0.001).
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Figure 5. Gene regulation by 25(OH)D3 and 1α,25-(OH)2D3 during the osteogenic differentiation of 
hMSCs. Real-time quantitative PCR was used to determine the induction of secreted phosphoprotein 1 (SPP1) 
(a,b), bone gamma-carboxyglutamate protein (BGLAP) (c,d), and runt related transcription factor 2 (RUNX2) 
(e,f) mRNA in response to the indicated concentrations of 25(OH)D3 or 1α ,25-(OH)2D3 in the hMSCs during 
three weeks of treatments. Relative mRNA expression was normalised to the control gene ribosomal protein 
lateral stalk subunit P0 (RPLP0) and fold inductions were calculated in reference to vehicle control, which is set 
as 1. Results are expressed as means ± SD (n = 3, *P < 0.05, **P < 0.01, and ***P < 0.001).
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Whether the osteogenic effect of 25(OH)D3 on hMSCs is direct or indirect via its metabolites requires an 
in-depth analysis. We and others have shown that 25(OH)D3 is an active hormone without being converted into 
1α ,25-(OH)2D3 in various types of cells and also in vivo9–14,16,17,41. In addition, a 25(OH)D3 analogue that cannot 
be 1α -hydroxylated exhibits anti-proliferative activity18. Our systematic study of global gene expression clarifies 
distinct roles of 25(OH)D3 and 1α ,25-(OH)2D3 and also reveals the direct genomic action of 25(OH)D3 by using 
CYP27B1 knockout cells20. In this study, the osteogenesis-stimulating effect of 25(OH)D3 is presumably not medi-
ated by 1α ,25-(OH)2D3 produced by hMSCs because the mRNA expression of CYP27B1 in the hMSCs was very 
low and 1α ,25-(OH)2D3 could not be detected in the conditioned media. It should be noted that our data do not 
indicate the absence of CYP27B1 in hMSCs. The HPLC method we used to measure 1α ,25-(OH)2D3 may have a 
low sensitivity since it used a UV detector. In earlier studies using radioimmunoassay or enzyme immunoassay, 
1α ,25-(OH)2D3 at pM was detected after treatment with 1000 nM 25(OH)D3, and the authors suggested that the 
action of 25(OH)D3 was mediated by CYP27B1 enzyme2,3. However, 1–10 nM 1α ,25-(OH)2D3 is required to 
exert biological effects in vitro. It is possible that intracellular concentration of 1α ,25-(OH)2D3 is high enough to 
induce biological effect. Altogether, the added 25(OH)D3 and cell-produced 1α ,25-(OH)2D3 together regulate cell 
proliferation and differentiation.
We found that 25(OH)D3 at 250–500 nM and 1α ,25-(OH)2D3 at 1–10 nM increased the mRNA expression of 
CYP24A1, which suggests a possibility that the resulting 24 R,25-dihydroxyvitamin D3 [24 R,25-(OH)2D3] and 
probably also 1α ,24 R,25-trihydroxyvitamin D3 [1α ,24 R,25-(OH)3D3] could play a role in osteogenesis. Indeed, 
Figure 6. Regulation by 25(OH)D3 and 1α,25-(OH)2D3 on bone gamma-carboxyglutamate protein 
secretion and intracellular expression in hMSCs. (a,b) Bone gamma-carboxyglutamate protein secretion 
in culture media of hMSCs was measured according to the procedure of the Gla-type osteocalcin EIA kit 
during four weeks of treatments with 25(OH)D3 or 1α ,25-(OH)2D3 at the indicated concentrations. Results are 
expressed as means ± SD. For 25(OH)D3 n = 3 and for 1α ,25-(OH)2D3 n = 2. (c–e) Intracellular bone gamma-
carboxyglutamate protein staining was performed in 0.1% ethanol-treated hMSCs (c), 500 nM 25(OH)D3-
treated hMSCs (d), and 1 nM 1α ,25-(OH)2D3-treated hMSCs (e). Scale bars: 50 μ m in c and d, 20 μ m in e.  
Controls in which the primary antibody was replaced with non-immunised mouse IgG show no positive 
staining (data not shown).
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both 24 R,25-(OH)2D3 and 1α ,24 R,25-(OH)3D3 have been shown to induce osteogenic differentiation of either 
human osteoblasts42,43 or hMSCs44. The induction of the extracellular matrix mineralisation by 25(OH)D3, but 
not by 1α ,25-(OH)2D3 found in this study is in agreement with an earlier report44. It is tempting to imagine 
that CYP27B1 and CYP24A1 enzymes are competing for the same substrate 25(OH)D3 in hMSCs. As CYP24A1 
was highly upregulated by 25(OH)D3 and both 24 R,25-(OH)2D3 and 1α ,25-(OH)2D3 were shown to inhibit 
CYP27B144,45, it could be reasonable to conclude that 1α ,25-(OH)2D3 produced in hMSCs, if any, may play a 
minor role in osteogenesis.
The use of 25OHD3 shows several advantages over 1α ,25-(OH)2D3 in both in vivo and ex vivo applications. 
Firstly, cell uptake of 25(OH)D3 is supposed to be greater than that of 1α ,25-(OH)2D3 due to the higher hydro-
phobicity of 25(OH)D3. Additionally, megalin-mediated endocytosis of 25(OH)D3-vitamin D binding protein 
complex is an important mechanism for cell uptake of 25(OH)D3 in many tissues and cells, including osteo-
blasts2,46. Secondly, 25(OH)D3 is more stable than 1α ,25-(OH)2D3. The half-life of 25(OH)D3 in the circulation 
is about two-three weeks while that of 1α ,25-(OH)2D3 is only less than four hours47–50. Since osteogenesis is 
not a fast process, stable vitamin D metabolite is preferable especially for in vivo applications. Thirdly, the pres-
ent study shows that the osteogenesis-inducing concentration of 25(OH)D3 is between 250–500 nM, which is 
well accepted in ex vivo applications and may even be tolerable in some in vivo applications as no significant 
rise in serum calcium was observed when 25(OH)D3 level was above 500 nM in healthy men51. The literature 
data and controlled dosing studies have confirmed that no vitamin D toxicity occurs at serum 25(OH)D3 levels 
below 500 nM52,53. In contrast, the osteogenesis-inducing concentration of 1α ,25-(OH)2D3 is 1–10 nM, which is 
much higher than its physiological levels (0.03–0.14 nM)24. It is worth noting that, here, we can only compare the 
osteogenesis-inducing concentrations of vitamin D metabolites with their serum concentrations since their tissue 
concentrations are unknown. Their tissue and intracellular concentrations are likely different from their serum 
concentrations when considering vitamin D metabolism and transport in target cells. Furthermore, we show 
here that the extracellular matrix mineralisation was induced by 25(OH)D3 but not by 1α ,25-(OH)2D3. 25(OH)
D3, despite its lower affinity to VDR, can stabilise the VDR-ligand binding domain in its agonistic conformation 
in the same way as 1α ,25-(OH)2D3 does12. Collectively, 25(OH)D3 exhibits more potent bone anabolic effects but 
less side effects particularly for clinical bone tissue engineering, in which cell-scaffold constructs accompanied 
with osteogenesis stimulating factors are implanted in an in vivo environment.
Figure 7. Mineralisation of the extracellular matrix of hMSCs. Mineralisation was determined by measuring 
the extracellular deposition of calcium in response to the treatment with 25(OH)D3 or 1α ,25-(OH)2D3 
at indicated concentrations during four weeks. Results are expressed as means ± SD (n = 2, *P < 0.05 and 
***P < 0.001).
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In conclusion, we demonstrate here that 25(OH)D3 at 250–500 nM induces osteogenesis of hMSCs. The find-
ing improves our understanding of the relationship between vitamin D and bone health. Our finding may also 
contribute to clinical bone tissue engineering.
Methods
Cell culture. Human mesenchymal stem cells (hMSCs) were obtained from Lonza (Walkersville, MD, USA). 
Cells were cultured and maintained in mesenchymal stem cell growth medium (Lonza, Walkersville, MD, USA) 
following the manufacturer’s instructions. Cells at passage 5 were used in the present study.
Differentiation of hMSCs. The hMSCs were plated in multiple-well plates at a density of 3000 cells/cm2 for 
one day to allow attachment in mesenchymal stem cell growth medium. At day 0, the medium was changed to 
osteogenic medium containing β -glycerophosphate and ascorbate-2-phosphate as supplied by the manufacturer, 
and supplemented with either 25(OH)D3 or 1α ,25-(OH)2D3 (Sigma-Aldrich, St. Louise, MO, USA) dissolved in 
ethanol at the concentrations indicated. The final concentration of ethanol in the culture medium was 0.1% in 
both hormone-treated cultures and vehicle controls. The medium was renewed three times a week.
RNA extraction and real-time quantitative PCR. Cells were cultured and differentiated in 6-well plates 
for 7, 14, and 21 days. Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) at each 
time point during differentiation experiments. The TRIzol samples were stored at − 80 °C for up to one month 
and were undergone the subsequent extraction procedure following the manufacturer’s instructions. All the RNA 
samples were converted into cDNA at the same experiment after day 21 to ensure the same reverse transcription 
efficiency. The cDNA synthesis was performed by using Transcriptor First Strand cDNA Synthesis Kit (Roche, 
Mannheim, Germany). All the cDNA samples were analysed in duplicate by real-time PCR in the same runs. 
For each gene, a standard curve with R2 greater than 0.996 was generated. This was not only to ensure that the 
unknown samples were within the standard range, but also to obtain the amplification efficiency for calculating 
the fold inductions as described previously54. PCR product quality was monitored using post-PCR dissociation 
curve analysis. All primers were synthesised by Research Biolabs, Singapore. The primer sequences are shown in 
Table 1.
The expression of secreted phosphoprotein 1 (SPP1) mRNA was measured using a FastStart DNA MasterPlus 
SYBR Green I kit on a LightCycler 1.5 (Roche) using the following protocol: 600 s preincubation at 95 °C followed 
by 40 cycles of 10 s denaturation at 95 °C, 3 s annealing at 59 °C for SPP1 or at 54 °C for ribosomal protein lateral 
stalk subunit P0 (RPLP0), and 6 s extension at 72 °C for SPP1 or 5 s for RPLP0.
The expression of cytochrome P450 family 24 subfamily A member 1 (CYP24A1), bone gamma-carboxyglutamate 
protein (BGLAP), and runt related transcription factor 2 (RUNX2) mRNA was measured using a Power SYBR 
Green PCR Master Mix kit (Applied Biosystems, Foster City, CA, USA) on an ABI Prism 7300 sequence detection 
system (Applied Biosystems). The expression of cytochrome P450 family 27 subfamily B member 1 (CYP27B1) 
mRNA was measured using a Fast SYBR Green Master Mix kit (Applied Biosystems, Foster City, CA, USA) on an 
ABI Prism 7500 sequence detection system (Applied Biosystems). The PCR cycling conditions were: 45 cycles of 
15 s at 95 °C and 1 min annealing/extension at 60 °C.
Quantitative alkaline phosphatase activity measurement. Alkaline phosphatase (ALPL) activ-
ity was measured according to the procedure of an ELF97 Endogenous Phosphatase Detection Kit (Molecular 
Probes, Oregon, USA) in a 96-well plate format. At day 7 and day 14, cells grown on 96-well plates were fixed 
with 3.7% paraformaldehyde for 10 min and then permeabilised with 0.2% Tween 20 in PBS for 15 min. After 
rinsing with distilled water twice, the cells were incubated with the ELF 97 phosphatase substrate in the detection 
buffer (1:20, 50 μ l/well) for 5 min in the dark. The fluorescence of the resulting product was directly measured by 
fluorescence spectroscopy (Tecan Safire II, Grödig, Austria) at an excitation wavelength of 345 nm and an emis-
sion wavelength of 530 nm. The cells were then washed with distilled water twice. The total cellular protein was 
Gene name Forward primer Reverse primer qPCR Instrument
Human secreted phosphoprotein 1, also called 
osteopontin (SPP1, NM_000582.2, NM_001040060.1, 
and NM_001040058.1)
5′ -GAGGGCTTGGTTGTCAGC-3′ 5′ -CAATTCTCATGGTAGTGAGTTTTCC-3′ LightCycler 1.5
Human ribosomal protein lateral stalk subunit P0 
(RPLP0, NM_053275.3 and NM_001002.3) 5′ -ACAGGGCGACCTGGAAGT-3′ 5′ -GGATCTGCTGCATCTGCTT-3′ LightCycler 1.5
Human cytochrome P450 family 24 subfamily A 
member 1 (CYP24A1, NM_000782) 5′ -GCCCAGCCGGGAACTC-3′ 5′ -AAATACCACCATCTGAGGCGTATT-3′ 
ABI Prism 7300 sequence 
detection system
Human runt related transcription factor 2 (RUNX2, 
NM_001015051.2, NM_001024630.2, and 
NM_004348.3)
5′ -CGTGGCCTTCAAGGTGGTA-3′ 5′ -CGGAGCTCAGCAGAATAATTTTC-3′ ABI Prism 7300 sequence detection system
Human bone gamma-carboxyglutamate protein 
(BGLAP, NM_199173) 5′ -AGCAAAGGTGCAGCCTTTGT-3′ 5′ -GGCTCCCAGCCATTGATACA-3′ 
ABI Prism 7300 sequence 
detection system
Human ribosomal protein lateral stalk subunit P0 
(RPLP0, NM_053275 and NM_001002) 5′ -AATCTCCAGGGGCACCATT-3′ 5′ -CGCTGGCTCCCACTTTGT-3′ 
ABI Prism 7300 sequence 
detection system
Human cytochrome P450 family 27 subfamily B 
member 1 (CYP27B1, NM_000785) 5′ -TTGGCAAGCGCAGCTGTAT-3′ 5′ -TGTGTTAGGATCTGGGCCAAA-3′ 
ABI Prism 7500 sequence 
detection system
Table 1.  Primer sequences.
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extracted by 50 μ l of 0.1% sodium dodecyl sulphate per well and was stored at − 80 °C. The protein concentration 
was measured by a BCA Protein Assay Kit (Pierce, Rockford, IL, USA). The ALPL activity was normalised against 
the total cellular protein concentration and expressed as relative levels against the solvent control.
ELISA assay. Cells were cultured and differentiated in 6-well plates for 7, 14, 21, and 28 days. At each time 
point, the conditioned media were collected and stored in aliquots at − 80 °C for the subsequent determinations 
of bone gamma-carboxyglutamate protein. The cells were washed once with PBS and lysed with a RIPA buffer 
containing protease inhibitor cocktail (Pierce, Rockford, IL, USA). The cell lysates were stored in aliquots at − 
80 °C for the subsequent measurements of protein concentration and immunoblotting of RUNX2 protein. After 
day 28, all the conditioned media were diluted 1 to 10 in the sample diluents provided by a Gla-type osteocalcin 
EIA kit and analysed in duplicate by the Gla-type osteocalcin EIA kit (Zymed Laboratories, Carlsbad, CA, USA) 
according to the manufactures’ protocol. The readings of the samples in the ELISA measurement were within the 
range of the standards (0–16 ng/ml). The protein concentrations in the cell lysates were measured in duplicate 
by a BCA protein assay kit. Subsequently the cell lysates were used in immunoblotting of RUNX2. The bone 
gamma-carboxyglutamate protein concentrations were normalised against the cellular protein concentration and 
expressed as ng bone gamma-carboxyglutamate protein per mg cellular protein.
Mineralisation. Mineralisation was determined by measuring the extracellular deposition of calcium. Cells 
were cultured and differentiated in 12-well plates for 7, 14, 21, and 28 days. At each time point, cell culture media 
were removed and cells were washed with calcium-free DPBS twice followed by decalcification in 0.4 ml of 0.6 N 
hydrochloric acid per well for 24 h at 4 °C. The resulting extracts in hydrochloric acid were centrifuged at 2000 g 
for 10 min, and the supernatants were stored at − 20 °C. After day 28, calcium concentrations in hydrochloric 
acid supernatants were directly measured in duplicate using a Stanbio Total Calcium LiquiColor kit (STANBIO 
Laboratory, Boerne, TX, USA). According to the manufacturer’s instruction, a standard was included in every 
measurement. In the first time, calibration was done by making a 3-point-standard curve to verify the linearity.
After 24 h incubation with hydrochloric acid, the decalcified cell monolayers were washed with DPBS three 
times. The cellular protein was extracted with 0.2 ml of 0.1 N sodium hydroxide in 0.1% sodium dodecyl sulphate 
per well and stored at − 80 °C. The protein concentrations were measured in duplicate by a BCA protein assay kit. 
The results were expressed as ng calcium per μ g cellular protein.
Immunoblotting. Cell lysates were obtained from the 6-well plates that were used in ELISA assays. Protein 
concentrations were measured using a BCA protein assay kit. Cell lysates were subjected to sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis using a 10% gel. Protein bands were transferred to hybond-P PVDF 
transfer membranes (0.45 μ m pore; Amersham Biosciences, Little Chalfont, UK). After blocking of nonspecific 
binding sites with a SuperBlock blocking buffer (Pierce, Rockford, IL, USA) at room temperature for 2 h, the 
membranes were incubated with goat-anti-human RUNX2 antibody (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) at a dilution of 1:500 at 4 °C overnight. After being washed with TBS-0.1% Tween 20, the membranes 
were incubated with donkey-anti-goat horseradish peroxidase-conjugated IgG (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) at a 1:10000 dilution at room temperature for 1 h. The blots were detected by ECL Plus Western 
Blotting Detection Reagents (GE Healthcare, Buckinghamshire, UK) and exposed to x-ray film for 1 min.
Immunofluorescence. After differentiation, cells were cultured on 8-well CultureSlides (BD Bioscience, 
Franklin Lakes, NJ, USA) for 4 h and then fixed with 3.7% paraformaldehyde for 10 min at room temperature 
and thereafter permeabilised with 0.1% Triton X-100 for 10 min. After being blocked with 5% normal rabbit 
serum, the cells were incubated with mouse-anti-human bone gamma-carboxyglutamate protein antibody (R 
& D Systems, Minneapolis, MN, USA) at a dilution of 1:50 at 4 °C overnight. Controls included omission of 
the primary antibodies and incubating with nonimmunized mouse IgG (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). The secondary antibody rabbit-anti-mouse Cy5-conjugated IgG (AbD Serotec, Kidlington, Oxford, 
UK) was used at room temperature for one hour. All washings using PBS-0.2% Tween 20 were repeated 3 times, 
5 min each. The cells were then counterstained with VECTASHIELD mounting medium with DAPI (Vector 
Laboratories, Burlingame, CA, USA). Staining was viewed under a confocal microscope with a 40x water len 
(Fluoview 300, Olympus, Japan).
Statistics. Standard deviations were calculated by Microsoft Excel. One-way analysis of variance (ANOVA) 
followed by Holm-Sidak multiple comparison test (Figs 1, 4 and 7; SigmaPlot 11.0) was performed to determine 
the significances of differences between hormone-treated samples and solvent controls. Student’s t-test was per-
formed to determine the significance of difference between MCF-7 and hMSC cells (Fig. 2; SigmaPlot 11.0). 
Differences of P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***) were considered significant.
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